February 9, 2016 11:22am
Financial results/ earnings is a ‘scorecard’ of public stem, cell and gene therapy regenerative medicine companies.
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
Members only. Please login.